rs1062033 — CYP19A1

CYP19A1 rs1062033 — The Aromatase Regulatory Switch and Bone Health

Aromatase — encoded by CYP19A1 on chromosome 15 — is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone) in peripheral tissues. Unlike the ovaries and testes, which produce estrogen in bulk, bone, fat, liver, brain, and breast tissue rely on local aromatase activity to maintain estrogen sufficiency around individual cells. rs1062033 sits approximately 12 kilobases upstream of the CYP19A1 translation start site in a regulatory region that controls which tissues express aromatase and in what amounts. This variant alters the binding of CEBPβ¹¹ CEBPβ
CCAAT/enhancer-binding protein beta, a transcription factor that regulates tissue-specific gene expression to the promoter, producing allele-specific differences in aromatase expression that downstream affect local estrogen concentrations — particularly in bone.

The Mechanism

The rs1062033 C>G change lies in an intronic regulatory region of CYP19A1 that acts as a tissue-specific promoter element. Electrophoretic mobility shift assays demonstrated that the C and G alleles bind the CEBPβ transcription factor with different affinities, and transient transfection experiments in osteoblastic cells showed allele-specific differences in luciferase reporter activity when a CEBPβ expression vector was co-introduced. Critically, differential allelic expression was confirmed directly in human bone tissue samples — not just in cell culture — making this one of the few CYP19A1 regulatory variants with direct in-tissue functional evidence rather than predicted regulatory effects alone.

The practical consequence flows through estrogen's effects on bone remodeling: estradiol suppresses osteoclast activity (bone breakdown) and supports osteoblast survival (bone formation). Women with alleles that sustain higher local aromatase activity in bone cells maintain greater estrogen-driven bone protection even as circulating ovarian estrogen declines after menopause. The interaction with vitamin D and calcium is indirect: estrogen upregulates calcium absorption in the gut (via calcium-binding protein calbindin-D9k²² calcium-binding protein calbindin-D9k
CALB1) and reduces urinary calcium loss — so allele-driven differences in aromatase activity propagate into effective calcium and vitamin D utilization in bone.

The Evidence

The foundational study by Riancho et al. 2009³³ Riancho et al. 2009
J Bone Miner Res — 1,163 postmenopausal women; rs1062033 as a true regulatory polymorphism with CEBPβ-binding evidence and allele-specific expression in human bone showed that opposing homozygotes (CC vs. GG) differed by 4.2% in whole-cohort BMD, a difference that expanded to 7.3% in women older than 67 — the age group with the greatest cumulative loss of ovarian estrogen support. This dose-response pattern across age is consistent with a lifetime accumulation of allele-driven differences in local bone estrogen signaling.

A Chinese Han case-control study Chen et al. 2024⁴⁴ Chen et al. 2024
Bladder cancer; 217 cases, 550 controls; OR=0.36 for G vs. C, FDR-p<0.001; rs1062033 correlated with CYP19A1 expression in whole blood independently confirmed that rs1062033 modifies CYP19A1 expression levels in blood, and found the G allele strongly protective against bladder cancer — a tissue where estrogen signaling is known to influence carcinogenesis risk.

The variant also modifies hormone circulating levels in response to environmental exposures. Kopp et al. 2016⁵⁵ Kopp et al. 2016
BMC Cancer — 687 cases/controls; rs1062033 associated with estrone sulphate levels (p=0.007) and interacted with alcohol to influence circulating hormone concentrations (p-interaction=0.03) demonstrated that the genotype influences baseline circulating estrone sulphate independently of hormone replacement therapy, and that the gene-environment interaction with alcohol is allele-specific.

Practical Actions

The primary clinical implication of this variant is in bone health for postmenopausal women. Carriers of two C alleles have lower aromatase-driven local estrogen in bone tissue, particularly relevant after menopause when peripheral aromatization becomes the dominant estrogen source. For these individuals, optimizing the cofactors that amplify bone-protective signaling — adequate vitamin D for calcium absorption, calcium intake distributed across meals for absorption efficiency, and weight-bearing activity to provide mechanical stimulus — becomes more important than for GG carriers, who retain higher local aromatase expression. Bone density monitoring starting from perimenopause is advisable to detect loss early when intervention is most effective.

Men also express aromatase in bone tissue, and testosterone therapy outcomes differ by rs1062033 genotype — indicating the variant's regulatory role in bone is not sex-exclusive, though the effect is smaller and evidence thinner in men.

Interactions

rs1062033 interacts epistatically with the IL-10 promoter variant rs1800896 in Alzheimer's disease risk — but only in women, with a synergy factor of 1.94 in the Epistasis Project (1,757 AD cases, 6,294 controls). The proposed mechanism involves local brain estrogen synthesis: aromatase is expressed in neurons and astrocytes, and locally produced estradiol modulates neuroinflammatory signaling via estrogen receptor beta. When aromatase activity is lower (CC genotype) AND IL-10 production is impaired (rs1800896 risk allele), the combined inflammatory environment in postmenopausal brain tissue may compound Alzheimer's risk beyond either variant alone. This interaction is not yet actionable as an independent clinical signal, but it illustrates the reach of aromatase regulation beyond bone.

rs700518 (also in CYP19A1, ~12 kb away) is the most studied bone-BMD variant in this gene and has a more robust evidence base for BMD effects in both sexes. Both variants modulate aromatase expression in bone but through distinct regulatory elements; their combined effect has not been formally characterized.